{"entity":{"id":"hyoscine","kind":"drug","name":"Hyoscine (scopolamine): butylbromide and hydrobromide","aka":["scopolamine","hyoscine butylbromide","hyoscine hydrobromide","butylscopolamine"],"tldr":"Hyoscine comes in two forms. Hyoscine butylbromide eases gut cramps and is the first medicine NICE suggests for sickness from a blocked bowel in the last days of life; either form can be tried for noisy breathing from secretions.","summary":"The UK SmPC for Buscopan ampoules (hyoscine butylbromide) covers acute spasm such as renal or biliary colic and diagnostic procedures where spasm is a problem; the US Transderm Scop patch (hyoscine hydrobromide) covers prevention of motion sickness and postoperative nausea and vomiting. NICE NG31 suggests hyoscine butylbromide as first-line treatment for nausea or vomiting with obstructive bowel disorders in the last days of life, with octreotide if symptoms do not improve within 24 hours, and lists both salts among the options for noisy respiratory secretions (off-label in December 2015). MASCC 2022 suggests hyoscine butylbromide may help abdominal pain in malignant bowel obstruction and may be inferior to octreotide for vomiting. The Transderm Scop NDA was approved on 31 December 1979.","status":"approved","asOf":"2026-11-11","wikipedia":"https://en.wikipedia.org/wiki/Scopolamine","links":[{"label":"UK SmPC (emc): Buscopan ampoules (hyoscine butylbromide)","url":"https://www.medicines.org.uk/emc/product/890/smpc"},{"label":"US label (DailyMed): Transderm Scop (hyoscine hydrobromide)","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b877a694-a1d0-4280-937a-a06820b12a88"},{"label":"NICE NG31: Care of dying adults in the last days of life, recommendations","url":"https://www.nice.org.uk/guidance/ng31/chapter/Recommendations"},{"label":"Davis et al., MASCC recommendations for the management of malignant bowel obstruction in advanced cancer (Support Care Cancer 2022)","url":"https://doi.org/10.1007/s00520-022-06889-8"}],"tags":["supportive","generic","supportive-care-gaps-2026-11"],"related":["glycopyrronium","haloperidol"],"cancers":[],"sections":[],"technologies":["palliative-care"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo supportive care gap fill (DailyMed, openFDA, Drugs@FDA, emc SmPCs, NICE, ESMO, ASCO, MASCC, SITC, ASTCT, ITAC, Europe PMC)","editedOn":"2026-11-11"},"brand":"Buscopan / Transderm Scop","modality":"Antimuscarinic (anticholinergic)","supportive":true,"mechanism":"Blocks muscarinic receptors: the butylbromide salt relaxes gut and urinary smooth muscle without entering the brain much; the hydrobromide salt acts centrally against nausea and reduces secretions.","approvals":[{"region":"US","year":1979,"indication":"Hydrobromide patch: prevention of motion sickness and postoperative nausea and vomiting","note":"Year is the Transderm Scop NDA 017874 approval (Drugs@FDA); the butylbromide salt is not marketed in the US"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/hyoscine/","neighbours":{"drug":[{"id":"glycopyrronium","kind":"drug","name":"Glycopyrronium bromide","route":"/drugs/glycopyrronium/"},{"id":"haloperidol","kind":"drug","name":"Haloperidol","route":"/drugs/haloperidol/"}],"technology":[{"id":"palliative-care","kind":"technology","name":"Early integrated palliative care","route":"/technologies/palliative-care/"}]}}